# VEEV (Veeva Systems Inc.) - SEC Filings Summary

**Generated:** 2025-11-29
**Sources:** 10-K (FY2025, filed 2025-03-24), 10-Q (Q3 FY2026, filed 2025-11-21), Proxy DEF 14A (filed 2025-05-05)

---

## COMPANY BASICS

**CIK:** 0001393052
**Headquarters:** Pleasanton, California
**Industry:** Cloud software for life sciences industry
**Stock Exchange:** NYSE (VEEV)
**IPO Date:** October 2013
**Fiscal Year End:** January 31

---

## FINANCIAL SNAPSHOT (as of 2025-10-31, Q3 FY2026)

**Balance Sheet:**
- Total Assets: $8.10 billion
- Cash & Equivalents: $1.66 billion
- Total Equity: $7.04 billion
- Total Liabilities: $1.06 billion
- Cash & Short-term Investments: $6.6 billion (includes $5.2B as of 2025-01-31)

**Income Statement (9 months ended 2025-10-31):**
- Total Revenue: $2.36 billion (up 16% YoY)
- Subscription Services Revenue: $1.98 billion (84% of total, up 18% YoY)
- Professional Services Revenue: $383 million (16% of total, up 10% YoY)
- Operating Income: $670 million
- Net Income: $665 million
- Gross Profit: $1.79 billion (76% gross margin)

**Cash Flow (9 months ended 2025-10-31):**
- Operating Cash Flow: $1.31 billion
- Free Cash Flow: $1.31 billion (after minimal capex)

**Full Fiscal Year 2025 (ended 2025-01-31):**
- Total Revenue: $2.75 billion (up 16% YoY from $2.36B in FY2024)
- Subscription Revenue: $2.29 billion (up 20% YoY)
- Net Income: $714 million (up from $526M in FY2024)

**Customer Base (as of 2025-01-31):**
- Total Customers: 1,477
- Commercial Solutions Customers: 730
- R&D Solutions Customers: 1,125
- Top 10 Customers: 28% of total revenues

---

## BUSINESS MODEL & PRODUCTS

**Revenue Split by Product Area (Q3 FY2026):**
- Commercial Solutions: 47% of subscription revenue (45% of total revenue)
  - Veeva Commercial Cloud (CRM)
  - Veeva Data Cloud
- R&D Solutions: 53% of subscription revenue (55% of total revenue)
  - Veeva Development Cloud
  - Veeva Quality Cloud

**Geographic Revenue Mix (9 months ended 2025-10-31):**
- North America: 60%
- Europe: 28%
- Asia Pacific & Other: 12%

**Key Products:**
- Veeva CRM (legacy on Salesforce platform, migrating to Vault CRM by Sept 2030)
- Vault CRM (built on Veeva Vault platform)
- Veeva Vault Platform
- Veeva Development Cloud
- Veeva Quality Cloud
- Veeva Commercial Cloud
- Veeva Data Cloud
- Veeva Crossix (data analytics)
- Veeva Business Consulting

---

## KEY HISTORICAL FACTS & TIMELINE

**Company History:**
- **Founded:** 2007 (incorporated in Delaware)
- **Founder & CEO:** Peter P. Gassner (continues as CEO)
- **IPO:** October 2013 (NYSE: VEEV)

**Major Strategic Developments:**
- **Platform Transition:** Migrating from Salesforce-based Veeva CRM to proprietary Vault CRM platform
  - Veeva CRM will be supported until September 1, 2030
  - Some large customers have chosen to switch to Salesforce instead (noted in filings)

**Recent Acquisitions & Expansions:**
- Multiple acquisitions mentioned in filings (specific details include purchased intangibles being amortized)
- Expansion into Business Consulting services
- Crossix acquisition (data analytics for healthcare)

---

## MANAGEMENT & GOVERNANCE

**Executive Leadership:**
- **CEO & Founder:** Peter P. Gassner (critical to company vision and strategy per risk factors)
- **CFO:** [Name not extracted from available sections]

**Board Composition:** [Details in proxy statement - file too large to fully parse]

**Employee Count:** Not specifically disclosed in extracted sections, but significant headcount growth noted in operating expenses

**Work Policy:** "Work Anywhere" policy - employees can work from office or home with job-specific restrictions

---

## MAJOR RISKS & RED FLAGS

### Critical Risks Identified in 10-K/10-Q:

**1. CRM Platform Migration Risk (HIGH PRIORITY):**
- Migrating from Salesforce platform to proprietary Vault CRM
- Risk of customer churn during migration
- Salesforce now competing directly with enhanced life sciences CRM (partnered with IQVIA)
- Some large customers already announced switch to Salesforce

**2. Customer Concentration:**
- Top 10 customers = 28% of revenue
- Loss of major customer could significantly impact growth

**3. Industry Concentration:**
- Nearly 100% of revenue from life sciences industry
- Vulnerable to regulatory changes affecting pharma/biotech
- Drug pricing reforms (Inflation Reduction Act) could reduce customer spending
- Funding environment for early-stage biotech affects demand

**4. Security & Cybersecurity:**
- Handles sensitive patient data (PHI), clinical trial data
- Elevated risk due to geopolitical tensions (Ukraine, Middle East)
- AI-powered attacks becoming more sophisticated

**5. Competitive Pressure:**
- Salesforce (primary CRM competitor) + IQVIA partnership
- IQVIA, Dassault Systemes, Oracle, Microsoft in various product areas
- Competitors offering price concessions due to macro environment

**6. Macroeconomic & Geopolitical:**
- Life sciences customers delaying projects due to macro uncertainty
- Tariffs and trade policy changes could impact customer spending
- Interest rates affecting biotech funding
- Russia/Ukraine conflict, Middle East tensions

**7. Litigation:**
- Currently being sued for alleged trade secret misappropriation (significant damages possible)
- Litigation settlement charges: $30.6M in 9 months ended 2025-10-31

**8. Regulatory Compliance:**
- Solutions must comply with FDA, GxP, electronic records regulations
- Physician Payments Sunshine Act compliance requirements
- International data privacy laws (GDPR, etc.)

**9. Technology Infrastructure:**
- Depends on AWS and Salesforce for infrastructure
- Service disruptions could damage reputation

**10. Talent Retention:**
- Intense competition for skilled employees
- Stock compensation value decline affects recruiting

---

## OPERATIONAL HIGHLIGHTS & TRENDS

**Positive Trends:**
- Strong revenue growth: 16% YoY (FY2025), maintaining in FY2026
- Subscription revenue growing faster than professional services
- R&D Solutions growing faster than Commercial Solutions (strategic shift)
- Very high gross margins: 86-87% for subscription services
- Strong profitability: 24-26% net margin
- Excellent cash generation: $1.3B operating cash flow (9 months)
- Low debt, strong balance sheet with $6.6B cash/investments

**Concerns:**
- Professional services gross margin declining: 18% (Q3 FY2026) vs 22% (Q3 FY2025)
- Sales cycle lengthening - increased customer scrutiny
- Some customers reducing sales reps (impacting CRM demand)
- Litigation costs increasing

**Tax Impact:**
- Effective tax rate: 24.2% (9 months FY2026) vs 23.1% prior year
- One Big Beautiful Bill Act (OBBBA) impact: restored immediate R&D expensing
- OBBBA increased operating cash flow significantly in FY2026

---

## FINANCIAL PERFORMANCE TRENDS

**Revenue Growth by Year:**
- FY2023: $2.16 billion
- FY2024: $2.36 billion (+10%)
- FY2025: $2.75 billion (+16%)
- FY2026 (9 months): $2.36 billion (on track for ~$3.1B annualized)

**Net Income Growth:**
- FY2023: $488 million
- FY2024: $526 million (+8%)
- FY2025: $714 million (+36%)
- FY2026 (9 months): $665 million

**Customer Growth:**
- FY2023: 1,388 customers
- FY2024: 1,432 customers (+3%)
- FY2025: 1,477 customers (+3%)

---

## UNUSUAL ACTIVITIES & SUSPICIOUS PATTERNS

**Litigation Settlement Charges:**
- $30.6 million in litigation settlement-related charges (9 months FY2026)
- $5.0 million in same period prior year
- Trade secret misappropriation lawsuit ongoing (could result in "significant damages")

**CEO Stock Compensation:**
- 2018 equity grant to CEO fully recognized in prior year
- New equity grant to CEO in Q2 FY2026 (July 2024)
- Increased G&A expenses due to CEO compensation

**Customer Losses:**
- Large Veeva CRM customer publicly announced switch to Salesforce
- Multiple customers "may in the future choose" to switch per risk factors
- Some customer consolidation reducing user counts

**Russian Operations:**
- Limited operations in Russia, but customers reducing Ukraine users
- EU sanctions prohibit enterprise software sales to Russia
- "Do not currently have locations or employees in Russia"

**Stock-Based Compensation:**
- $354 million in 9 months FY2026 (15% of revenue)
- $322 million in 9 months FY2025
- Significant non-cash expense affecting GAAP vs non-GAAP results

---

## KEY METRICS SUMMARY

| Metric | Value | Period |
|--------|-------|--------|
| Total Revenue | $2.75B | FY2025 |
| Revenue Growth | 16% YoY | FY2025 |
| Gross Margin | 76% | Q3 FY2026 |
| Operating Margin | 28% | 9mo FY2026 |
| Net Margin | 28% | 9mo FY2026 |
| Operating Cash Flow | $1.31B | 9mo FY2026 |
| Total Customers | 1,477 | FY2025 |
| Cash & Investments | $6.6B | Q3 FY2026 |
| Total Debt | $0 | Q3 FY2026 |
| Employees | Not disclosed | - |

---

## FORWARD-LOOKING CONSIDERATIONS

**Growth Drivers:**
- R&D Solutions expanding faster than Commercial
- Vault platform adoption increasing
- International expansion (41% revenue from outside North America)
- New product development (AI capabilities mentioned)
- Business consulting revenue growing

**Headwinds:**
- CRM platform migration creating customer churn risk
- Competitive pressure from Salesforce-IQVIA partnership
- Macro uncertainty affecting life sciences spending
- Regulatory risks (drug pricing, FDA funding cuts)
- Lengthy sales cycles (12+ months)

**Strategic Priorities:**
- Complete CRM migration to Vault platform by 2030
- Expand R&D Solutions portfolio
- Maintain profitability while investing in growth
- Retain talent in competitive market
- Manage cybersecurity risks

---

## DOCUMENT REFERENCES

- 10-K Annual Report (FY2025): veev-20250131.htm (163KB, filed 2025-03-24)
- 10-Q Quarterly Report (Q3 FY2026): veev-20251031.htm (117KB, filed 2025-11-21)
- Proxy Statement DEF 14A: ny20039511x1_def14a.htm (119KB, filed 2025-05-05)
- CIK: 0001393052
- All filings available at: https://www.sec.gov/edgar/browse/?CIK=1393052

---

**Note:** This summary focuses on factual data with dates and numbers. Some executive compensation and detailed board information from the proxy statement could not be fully extracted due to HTML complexity. For complete details, refer to the original filings.
